I strongly recommend you don’t invest in Clinuvel at all.... I’m confident that Clinuvel know a lot more about what they are doing than what you presume to know. XP and variagate porphyria are boons, and I’m quite sure they will be insurance companies in the US that will cover vitiligo, especially when the per unit price is reduced substantially ($500-2k). An inflection point will occur where the per unit price is affordable to everyone and suddenly the drug becomes available to large swaths of the population. Then there’s offlabel...
The irony here is there are many pharmaceuticals in the world running up substantial losses and drugs in Phase 1-2 with over the top share prices that aren’t justified in any sense. Clinuvel however has a drug in the European market with 40% yoy growth, $48-50 million cash in hand, and zero debt which more than justifies a potentially elevated share price. Say what you will about Clinuvel, but the potential is too enormous to foolishly ignore.
- Forums
- ASX - By Stock
- CUV
- Ann: Chair Letter to Shareholders
Ann: Chair Letter to Shareholders, page-17
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.59 |
Change
0.470(3.11%) |
Mkt cap ! $780.7M |
Open | High | Low | Value | Volume |
$15.12 | $15.99 | $15.12 | $2.345M | 149.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $15.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.66 | 92 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 15.290 |
1 | 198 | 15.110 |
1 | 100 | 15.000 |
2 | 1371 | 14.800 |
1 | 100 | 14.530 |
Price($) | Vol. | No. |
---|---|---|
15.700 | 200 | 1 |
15.850 | 500 | 1 |
15.870 | 452 | 1 |
15.880 | 1000 | 1 |
15.900 | 1000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online